Epileptic spasms in CDKL5 deficiency disorder: Delayed treatment and poor response to first‐line therapies

We aimed to assess the treatment response of infantile‐onset epileptic spasms (ES) in CDKL5 deficiency disorder (CDD) vs other etiologies.

[1]  E. Pestana-Knight,et al.  CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging Treatment , 2022, CNS Drugs.

[2]  A. Bergin,et al.  Infantile spasms: Assessing the diagnostic yield of an institutional guideline and the impact of etiology on long‐term treatment response , 2022, Epilepsia.

[3]  M. King,et al.  Response to treatment and outcomes of infantile spasms in Down syndrome , 2022, Developmental medicine and child neurology.

[4]  E. Pestana-Knight,et al.  Current neurologic treatment and emerging therapies in CDKL5 deficiency disorder , 2021, Journal of Neurodevelopmental Disorders.

[5]  Anup D. Patel,et al.  Comparative Effectiveness of Initial Treatment for Infantile Spasms in a Contemporary US Cohort , 2021, Neurology.

[6]  D. Mei,et al.  CDKL5 deficiency disorder in males: Five new variants and review of the literature. , 2021, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[7]  Masahiro Ito,et al.  Clinical manifestations and epilepsy treatment in Japanese patients with pathogenic CDKL5 variants , 2021, Brain and Development.

[8]  L. Lagae,et al.  Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial , 2020, Annals of neurology.

[9]  Daniel W. Shrey,et al.  Felbamate in the treatment of refractory epileptic spasms , 2020, Epilepsy Research.

[10]  F. Jansen,et al.  Update on Drug Management of Refractory Epilepsy in Tuberous Sclerosis Complex , 2020, Pediatric Drugs.

[11]  Si-qi Hong,et al.  Prednisolone/prednisone as adrenocorticotropic hormone alternative for infantile spasms: a meta‐analysis of randomized controlled trials , 2020, Developmental medicine and child neurology.

[12]  C. Delanoé,et al.  Felbamate for infantile spasms syndrome resistant to first‐line treatments , 2019, Developmental medicine and child neurology.

[13]  Hoon-Chul Kang,et al.  Optimized Treatment for Infantile Spasms: Vigabatrin versus Prednisolone versus Combination Therapy , 2019, Journal of clinical medicine.

[14]  E. Pestana-Knight,et al.  Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical Review. , 2019, Pediatric neurology.

[15]  E. Pestana-Knight,et al.  CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development , 2019, Epilepsia.

[16]  J. Millichap,et al.  The ketogenic diet in children 3 years of age or younger: a 10-year single-center experience , 2019, Scientific Reports.

[17]  O. Dulac,et al.  New insights in phenomenology and treatment of epilepsy in CDKL5 encephalopathy , 2019, Epilepsy & Behavior.

[18]  D. Turkdoğan,et al.  Ketogenic diet as a successful early treatment modality for SCN2A mutation , 2019, Brain and Development.

[19]  A. Mühlebner,et al.  Efficacy and tolerability of the ketogenic diet versus high‐dose adrenocorticotropic hormone for infantile spasms: A single‐center parallel‐cohort randomized controlled trial , 2019, Epilepsia.

[20]  F. Hickey,et al.  Infantile Spasms in Children With Down Syndrome: Identification and Treatment Response , 2019, Global pediatric health.

[21]  M. Likeman,et al.  Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spasms: 18-month outcomes of an open-label, randomised controlled trial. , 2018, The Lancet. Child & adolescent health.

[22]  Jyh-Feng Lu,et al.  SCN2A mutation in an infant presenting with migrating focal seizures and infantile spasm responsive to a ketogenic diet , 2018, Brain and Development.

[23]  Hoon-Chul Kang,et al.  The Efficacy of Ketogenic Diet for Specific Genetic Mutation in Developmental and Epileptic Encephalopathy , 2018, Front. Neurol..

[24]  Hoon-Chul Kang,et al.  Targeted gene panel and genotype-phenotype correlation in children with developmental and epileptic encephalopathy , 2018, Epilepsy Research.

[25]  G. Zaccara,et al.  Efficacy of ketogenic diet for infantile spasms: A systematic review , 2018, Acta neurologica Scandinavica.

[26]  Anup D. Patel,et al.  The impact of hypsarrhythmia on infantile spasms treatment response: Observational cohort study from the National Infantile Spasms Consortium , 2017, Epilepsia.

[27]  A. Mallick,et al.  Caregiver's perception of epilepsy treatment, quality of life and comorbidities in an international cohort of CDKL5 patients. , 2017, Hippokratia.

[28]  A. Bergin,et al.  Use of the ketogenic diet to manage refractory epilepsy in CDKL5 disorder: Experience of >100 patients , 2017, Epilepsia.

[29]  M. Likeman,et al.  Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial , 2017, The Lancet Neurology.

[30]  Sucheta Joshi,et al.  Response to treatment in a prospective national infantile spasms cohort , 2016, Annals of neurology.

[31]  Anup D. Patel,et al.  Improving the inter-rater agreement of hypsarrhythmia using a simplified EEG grading scale for children with infantile spasms , 2015, Epilepsy Research.

[32]  Raman Sankar,et al.  Hypsarrhythmia assessment exhibits poor interrater reliability: A threat to clinical trial validity , 2015, Epilepsia.

[33]  I. Scheffer,et al.  A distinctive seizure type in patients with CDKL5 mutations: Hypermotor-tonic-spasms sequence , 2011, Neurology.

[34]  W. Arts.  CDKL5 gene‐related epileptic encephalopathy: electroclinical findings in the first year of life , 2011, Developmental medicine and child neurology.

[35]  F. Duffy,et al.  Rufinamide for the treatment of epileptic spasms , 2011, Epilepsy & Behavior.

[36]  A. Renieri,et al.  Seizures and electroencephalographic findings in CDKL5 mutations: Case report and review , 2007, Brain and Development.

[37]  J. Osborne,et al.  Randomized trial of vigabatrin in patients with infantile spasms. , 2002, Neurology.

[38]  L. Hirsch,et al.  Experience with the ketogenic diet in infants. , 2001, Pediatrics.

[39]  M. Chang,et al.  Efficacy of Treatments for Infantile Spasms: A Systematic Review , 2017, Clinical neuropharmacology.

[40]  P. Striano,et al.  Retrospective evaluation of low long-term efficacy of antiepileptic drugs and ketogenic diet in 39 patients with CDKL5-related epilepsy. , 2016, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.